


PTO/SB/08A				<b>Compleat if Known</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/038,080
				Filing Date	01-03-2002
				Confirmation Number	7358
				First Named Inventor	P. Isakson
				Group Art Unit	1627
				Examiner Name	Friend
Sheet	1	of	2	Attorney Docket No.	PHA 4142.2 (2891/3)

RECEIVED

TECH CENTER 1600/2900

MAR 27 2003



U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code <sup>2</sup> (if known)				
JE	74	4,595,699	B1	Terada et al.	06-17-1986		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
JE	75	WO	94/02448	A1	The Wellcome Foundation Ltd.	02-03-1994	
	76	WO	95/15316	A1	G.D. Searle & Co.	06-08-1995	
	77	WO	96/03385	A1	G.D. Searle & Co.	02-08-1996	
	78	WO	96/41645	A1	G.D. Searle & Co.	12-27-1996	
OTHER ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>6</sup>
JE	79	BREEDVELD F., "Tenidap: A Novel Cytokine-Modulating Antirheumatic Drug for the Treatment of Rheumatoid Arthritis." Rheumatology, 1994, pp. 31-44, Vol. 23, Suppl. 100.					

Examiner Signature		Date Considered	6/14/03
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

**BEST AVAILABLE COPY**

<b>PTO/SB/08A</b>  <b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Comple</b>		<b>if Known</b>	
		Application Number		10/038,080	
		Filing Date		01-03-2002	
		Confirmation Number		7358	
		First Named Inventor		P. Isakson	
		Group Art Unit		1627	
		Examiner Name		Friend	
Sheet	2	of	2	Attorney Docket No.	PHA 4142.2 (2891/3)

RECEIVED  
 MAR 27 2003  
 TECH CENTER 1600/2900

JE	80	BARTLETT et al., "Substituted 3-phenyl-7H-thiazolo(3,2-b)1,2,4)triazin-7-ones as Antiinflammatory Agents with Immunomodulating Properties." <i>Drugs Under Experimental and Clinical Research</i> , 1989, pp. 521-526, Vol. XV, Nos. 11/12.
JE	81	SHAW et al., "Drugs Affecting the Prostaglandin Synthetic Pathway and Rat Heart Allograft Survival." <i>Advances in Prostaglandin, Thromboxane, and Leukotriene Research</i> , 1985, pp. 219-220, Vol. 13.
NO DAK	82	<del>FIMIANI et al., "Antitumoral and Immunoregulatory Effects on Macrophage Activities of Non-steroidal Anti-inflammatory Drugs." <i>Institute of General Pathology Chairs of Physiopathology and Immunology, University of Messina Medical School, Messina, Italy</i>, pp. 58-65.</del>
JE	83	BADGER et al., "Augmentation of Concanavalin A-induced Immunosuppression by Indomethacin." <i>Immunopharmacology</i> , 1982, pp. 149-162, Vol. 4, No. 2.
	84	SHELBY et al., "Effect of Prostaglandin Inhibitors on Transfusion-Induced Immune Suppresion." <i>Transplantation Proceedings</i> , 1986, pp. 1435-1436, Book II.
	85	LATTER et al., "The Effect of Indomethacin on Burn-Induced Immunosuppression." <i>Clinical and Laboratory Investigation</i> , 1987, pp. 246-252, Vol. 43, No. 2.
	86	TARAYRE et al., "Comparative Actions of Immunosuppressants, Glucocorticoids and Non-steroidal Anti-inflammatory Drugs on Various Models of Delays Hypersensitivity and on a Non-immune Inflammation in Mice." <i>Arzneimittel Forschung Drug Research</i> , 1990, pp. 1125-1131, Vol. 40, No. II.
	87	BRAUN et al., "Modificiation of Chemotherapy-Induced Immunosuppression in Lung Cancer Patients with Piroxicam." <i>Proceedings American Society of Clinical Oncology</i> , 1985, p. 223, Vol. 4.
	88	FUNG-LEUNG et al., "Tepoxalin, a Novel Immunomodulatory Compound, Synergizes with CSA in Suppression of Graft-Versus-Host Reaction and Allogeneic Skin Graft Rejection." <i>Transplantation</i> , 1995, pp. 362-368, Vol. 60, No. 4.
	89	NICKERSON-NUTTER et al., "The Effect of Leukotriene Synthesis Inhibitors in Models of Acute and Chronic Inflammation." <i>Arthritis &amp; Rheumatism</i> , 1996, pp. 515-521, Vol. 39, No. 3.
✓	90	ZHANG et al., "Tumor Necrosis Factor Alpha Stimulates Arachidonic Acid Metabolism in Human Osteoblastic Osteosarcomal Cells." <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1996, pp. 427-431, Vol. 54, No 6

Examiner Signature		Date Considered	6/14/03
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.